Skip to main content
Equibles
OWLT logo

OWLT · Owlet, Inc. · Metrics

Track OWLT — free

Use OWLT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OWLT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.17 -0.02 (-0.48%) At close · Oct 28 Q2 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — cleared Aug 14, 2026

The latest filing states the doubt was alleviated.

“In accordance with ASU No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements included in this quarterly report on Form 10-Q are issued.”
View the 10-Q filed Aug 14, 2026
Market Cap
$122.44M
Shares
29.22M
Volume · Oct 28 148.58K Avg daily vol (3M) 187.03K

OWLT metrics

76 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$4.17
Market cap
$122.44M

Price action

20 metrics
Price change (1W)
-2.1%
Price change (30D)
-18.0%
Price change (3M)
-19.0%
Price change (6M)
-17.5%
Price change (YTD)
-74.1%
Price change (1Y)
-54.9%
Trailing year
Price change (5Y)
—
52-week high
$16.52
52-week low
$4.03
Change from 52-week high
-74.6%
Change from 52-week low
+4.0%
Annualized volatility
80.3%
Annualized volatility (3M)
56.5%
Beta
2.3
RSI (14D)
37.7
Price vs SMA 50
-13.5%
Price vs SMA 200
-35.9%
Avg volume (3M)
186,560
Relative volume
0.3
Average dollar volume
$956,078

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
29.22M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.9×
reciprocal yield 110.6%
EV / EBITDA
—
EV / EBIT
—
P / sales
1.0×
reciprocal yield 97.5%
P / book
5.1
reciprocal yield 19.6%
FCF yield
-7.2%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-7.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.1×
reciprocal yield 89.7%
EV / revenue historical average (5Y)
1.4×
reciprocal yield 70.9%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-11

Profitability

9 metrics
Gross margin
54.8%
Operating margin
-6.3%
Trailing 12 months
Net margin
-7.7%
Gross profit (TTM)
$62.89M
Operating profit (TTM)
−$7.23M
Net income (TTM)
−$8.81M
Trailing 12 months
Diluted EPS (TTM)
$-0.35
FCF margin
-7.4%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.71

Growth

11 metrics
Revenue growth YoY
+29.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$114.86M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+81.4%
Year over year · more shares
Revenue CAGR (3Y)
+15.3%
Revenue CAGR (5Y)
+7.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-38.1%
Return on assets
-9.4%
Debt / equity
0.7
Current ratio
1.6
EBITDA (TTM)
−$6.54M
Free cash flow (TTM)
−$8.53M
Quick ratio
1.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$13.88M
Latest balance sheet
Cash & equivalents
$30.95M
Total assets
$93.57M
Total debt
$17.06M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$7.76M
Capital expenditures (TTM)
$762,000
R&D (TTM)
$15.87M
SG&A (TTM)
—
Stock compensation (TTM)
$12.94M
R&D / revenue
13.8%
Stock compensation / revenue
11.3%

Ownership (13F)

9 metrics
13F filers
60
13F filer change QoQ
-7
Institutional ownership
58.6%
Conviction holders (share of 13F filers)
3.4%
Crowding (high-turnover and private-fund holders)
43.3%
Private-fund adviser ownership
42.1%
Active holders' share change QoQ
-7.1%
Holder tenure
4.0
Price vs estimated holder cost
-40.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
3.7%

Short interest

3 metrics
Short interest
1.9%
Latest settlement · 4.8 days to cover
Days to cover
4.8d
Short-squeeze score
35 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1816708 CUSIP 69120X206 13F (30d) 5 filings 5 filers Visit website Investor relations